key: cord-1037425-03n42ijk
authors: Guarino, Maria; Esposito, Ilaria; Portella, Giuseppe; Cossiga, Valentina; Loperto, Ilaria; Tortora, Raffaella; Cennamo, Michele; Capasso, Mario; Terracciano, Daniela; Lanza, Alfonso Galeota; Di Somma, Sarah; Picciotto, Francesco Paolo; Morisco, Filomena
title: Humoral response to 2-dose BNT162b2 mRNA COVID-19 vaccination in liver transplant recipients.
date: 2022-01-20
journal: Clin Gastroenterol Hepatol
DOI: 10.1016/j.cgh.2022.01.012
sha: 66ca9d19715bbc36fd72c1d7d640ebb9fbcf3aa1
doc_id: 1037425
cord_uid: 03n42ijk

Background & Aims In the context of the Italian SARS-CoV-2 vaccination program, liver transplant (LT) recipients were prioritized for vaccine administration, although the lower response to vaccines is a well known problem in this population. We aimed to evaluate immunogenicity of BNT162b2 mRNA vaccine in LT recipients and healthy controls and to identify factors associated with negative response to vaccine. Methods We prospectively evaluated in a cohort of adult LT patients the humoral response (with anti-Spike protein IgG-LIAISON SARS-CoV-2 S1/S2-IgG chemiluminescent assay) at 1 and 3 months after 2-dose vaccination. A group of 307 vaccinated healthcare workers, matched by age and sex, served as controls. Results Overall, 492 LT patients were enrolled (75.41% male, median age 64.85 years). Detectable antibodies were observed in the 75% of patients with a median value of 73.9 AU/mL after 3 months from 2-dose vaccination. At multivariable analysis, older age (>40years, p=0.016), shorter time from liver transplantation (<5years, p=0.004), and immunosuppression with antimetabolites (p=0.029) were significantly associated with non-response to vaccination. Moreover, the LT recipients showed antibody titers statistically lower than the control group (103 vs 261 AU/ml, p<0.0001). Finally, both in controls and LT patients we found a trend of inverse correlation between age and antibody titers (correlation coefficient: -0.2023 and -0.2345, respectively). Conclusions Three months after vaccination, LT recipients showed humoral response in 75% of cases. Older age, shorter time from transplantation and use of antimetabolites were factors associated with non-response to vaccination and needed to be kept under close monitoring.

The SARS-CoV-2 infection (COVID- 19) pandemic rapidly spread in the first months of 2020 and at the end of 2020 an mRNA vaccine (BNT162b2) was approved (1) (2) . Solid organ transplant recipients are considered a vulnerable group at increased risk of severe disease and death in case of infection (3) . For this reason, this group of patients has been prioritized in the timeline schedule of the National Vaccination Program. Data about immunogenicity of vaccination in liver transplant (LT) recipients are poor since this population was excluded from clinical trials. Additionally, lower response to vaccination is a well-known problem in immunocompromised solid organ recipients due to the chronic immunosuppressive state (4) . Nonetheless, national and international transplant societies have recommended to prioritize vaccination for all recipients with a follow-up of more than 3 months post-liver transplant (5-6-7) .

Previous studies in the setting of influenza vaccination suggest that despite lower antibody and cellmediated immunity elicited by solid organ transplant recipients, vaccination has been significantly associated with lower rates of severe infection and complications (7) .

Concordant low immunogenicity has been reported by different recent studies conducted in LT recipients analysing small series of patients with a great heterogeneity in terms of timing of postvaccine response assessment, of vaccine administered (Moderna, Pfizer, Astra-Zeneca or Johnson & Johnson) and of type of response (humoral and/or cellular) analysed (8) (9) (10) (11) (12) (13) (14) (15) (16) .

In this scenario, the primary objective of the present study was to evaluate immunogenicity and safety of SARS-CoV-2 vaccination with Pfizer-BioNTech in a cohort of LT recipients, by quantifying the humoral response after 1 and 3 months. Secondary objectives were: 1. to compare the antibody response in LT recipients with a group of healthy subjects; 2. to explore the impact of different factors (i.e., age, type of immunosuppression, steroid treatment, comorbidities, etc) on elicited humoral immune responses to better stratify those at-risk for seronegative response; and 3. to study clinical reactogenicity of Pfizer-BioNTech as well as breakthrough infections in vaccinated LT recipients.

J o u r n a l P r e -p r o o f

This is a prospective study evaluating the effectiveness of SARS-CoV-2 vaccination with Pfizer-BioNTech in a cohort of adult LT recipients regularly followed up at two referral hospitals in Southern Italy (Cardarelli Hospital and Federico II Academic Hospital) in accordance with the Declaration of Helsinki.

The protocol was approved by the local ethic board of the promoting centre (Federico II University of Naples, n 214/2021). All patients and controls involved in the study provided written informed consent to participate.

From March 2021, transplant recipients were prioritzed in Italy to receive the Pfizer-BioNTech BNT162b2 vaccine, administered in two doses given 3 weeks apart, in the context of the national Covid-19 vaccination program launched in January 2021. The administration of vaccine was conducted according to the vaccination schedule specified in the BNT162b2 vaccine summary of product characteristics (17) .

In this prospective cohort, all consecutive LT patients who completed the 2-dose BNT162b2 vaccine series before May 20th, 2021, were included and followed up until August 15th, 2021.

After signing the informed consent, blood samples were collected at 3 time points: prior to 1 st dose, one month and three months after 2 nd dose of the BNT162b2 vaccine for detecting anti-Spike protein IgG (DiaSorin, Italy) (18).

Exclusion criteria for receiving the vaccine and entering the study included age < 18 years, transplantation within the last three months, and active SARS-CoV-2 infection. Of note, LT patients with simultaneous kidney (or other solid organ) transplantation have been excluded according to study design.

History of previous COVID-19 was not an exclusion criterion and patients were considered for vaccination three months after the infection.

Clinical data was obtained from patients' medical records and routine blood tests up to three months prior to the day of first dose administration. In particular, the following data were collected for analysis: age, gender, body mass index (BMI), comorbidities, transplant date, immunosuppressive drugs, use of steroids, history of retransplantation.

Healthcare workers of the Cardarelli Hospital and Federico II Academic Hospital who were offered the vaccination with BNT162b2 in-hospital served as controls. History of previous COVID-19 was registered. None of them received immunosuppressive treatment or had major comorbidities. Since the two populations were not matched for age and sex, a subgroup within the transplanted patients was selected and matched in a 1:1 ratio by sex and age class with controls. Accordingly, we selected two subpopulation consisting of 307 cases (LT recipients) and 307 controls (healthcare workers). J o u r n a l P r e -p r o o f Results A total of 916 patients who were actively followed at Cardarelli Hospital and Federico II Academic Hospital after liver transplantation were initially screened for BNT162b2 vaccine and the final population included 492 patients. All of these patients received the two doses within the 20 th of May, and they were prospectively and consecutively included in the study. A study flow-chart is depicted in Figure 1 . (Table 1) .

Detectable levels of antibodies were observed in 333/444 patients (75%) with a median value of 99.05 Data from the 48 patients who were seropositive at timepoint 0, indicating previous SARS-CoV-2 infection, were analysed separately.

At univariable analysis, comparing patients with negative versus positive serology to SARS-CoV-2 vaccination, the factors statistically significant associated with absence of humoral response were older age (>40 years, p=0.016), history of HCC as indication for LT (p 0.014), shorter time from liver transplantation (<5 years, p=0.004), presence of cardiovascular disease as comorbidity (p=0.028), immunosuppressive regimens with multiple drugs (p<0.001) and antimetabolite therapy (p<0.001) J o u r n a l P r e -p r o o f (Table 2) . At multivariable analysis, only age, baseline immunosuppression, and time from LT were significantly associated with vaccination non-response (Table 2) .

Additional analysis was separately conducted in patients with positive serology to vaccine comparing strongly positive patients (antibody titer>400AU/ml) versus other positive patients (antibody titer between 25 and 400AU/ml) to identify factors associated with higher humoral response. At univariable analysis, the factors statistically significant associated with a stronger humoral response were younger age (<40 yrs, p>0.001), and indication to LT (p=0.029 for viral infection and p=0.005 for "other indication" to LT (i.e. indication not including viral infection, alcoholic and not-alcoholic liver disease, or hepatocellular carcinoma). At multivariable analysis, only younger age was still significantly associated with strong response to the vaccine. Although knowledge is limited due to the absence of well-defined clinical trials in this special population, it is well established that the immune response elicited by vaccines is multi-faceted and that usually antibody and cell-mediated responses in solid organ transplanted subjects are less pronounced. In a systematic review, response varied in relation to the type of vaccine, age and type of organ transplanted (4), while some studies showed that additional doses or higher doses are useful to increase immunogenicity (19) . Nonetheless, it is important to underline that the interpretation of immunological response to vaccination in transplanted subjects is complex and needs to consider several variables such as the organ transplanted, timing from transplantation, age, current or past treatment, and comorbidities. According to this data, international and national societies recommended SARS-CoV-2 vaccination in all solid organ transplant recipients (12 years and older) as well as priority vaccination of their household members and caregivers to reduce infection risk for these vulnerable patients (5-6).

The results of the present study are in line with Boyarsky, showing that 67% of solid organ transplanted patients mounted a positive humoral response to SARS-CoV-2 vaccine after 3 months from the second dose (10) . Similarly, Strauss reported 81% of seropositivity after 1 month from 2dose vaccination in a cohort of 161 LT patients (14) , in contrast to initial results published by

Rabinovich showing a 47.5% rate after 1 month in a cohort of 80 LT subjects (8) . Additionally, they observed negative serologic response in patients of older age (>63 years), the use of high dose of prednisone in the past 12 months, and in treatment with regimens including antimetabolites and triple immunosuppressive therapy (8) . Our results confirm that older age and use of antimetabolite are factors associated with absence of humoral response to the vaccine, but we also identified the shorter time from liver transplantation as an additional risk factor, confirming data reported by Strauss (14), Herrera (13) and Mazzola (12) . It is well-known that the "immunosenescence" (i.e. an age-related dysregulation and decline of the immune system) has been associated with a weak response to vaccinations in older subjects (20) . We showed a correlation between age and antibody titer confirming the effect of immunosenescence. The increased risk of absent humoral response to SARS-CoV-2 vaccination in the first years after transplantation can be explained because of a higher level of immunosuppression during induction and in the immediate post-transplant period. Moreover, we showed a poor antibody response in LT patients undergoing immunosuppressive regimes containing antimetabolites. This finding has been observed in different settings because mycophenolic acid inhibits de novo purine biosynthesis in lymphocytes suppressing antibody production and cellmediated immune activity (21) (22) (23) . Finally, when compared to healthcare workers, LT patients showed a significantly reduced level of humoral response (103AU/ml vs 260AU/ml) confirming data reported by Rabinovich (8) .

Furthermore, our results confirmed that 2-dose vaccination with BNT162b2 elicits a vigorous immune response in previously COVID-19 exposed LT patients compared to SARS-CoV-2 naïve patients, as already reported in literature (24) .

Moreover, our 3 anecdotic cases of breakthrough infection after 2-dose vaccination sustain the evidence that BNT162b2 vaccine was effective in preventing symptomatic COVID-19, according to data demonstrating protection ranging between 70 and 95% in healthy individuals (25) . Therefore, we would strongly recommend COVID-19 vaccination in LT recipients, but we would like to highlight the relevance of vaccinating also their close contacts (family and caregivers) to reduce the risk of exposure. Additionally, even if LT patients showed a weak response to vaccination, they benefited in terms of morbidity and mortality compared to unvaccinated LT recipients (26) . However, LT patients need to be aware that they have a higher risk to be unprotected after vaccination compared to healthy individuals and thus, they should continue to practice strict COVID-19 precautions, such as social distancing and wearing masks. Furthermore, given many LT patients develop weak SARS-CoV-2 antibody responses after two doses of an mRNA-based vaccine, third doses have been authorized for immunocompromised subjects improving the immunogenicity of the vaccine in this vulnerable group, as showed by recent papers (27) (28) .

Finally, we also showed that BNT162b2 vaccine was well tolerated by LT patients, and none reported organ rejection or compromised graft function, even if there has also been concern that COVID-19 vaccination might contribute to organ rejection and graft dysfunction (29) .

The strengths of this study include its novelty. It is the first published report about SARS-CoV-2 vaccination in a large cohort of LT recipients (492 patients) undergoing the same vaccination schedule (BNT162b2). Secondly, to our knowledge, our data shows for the first time the humoral response after 1 and 3 months from 2-dose vaccination in LT recipients in comparison with a large controls group matched for age and sex.

Nonetheless, our study has some limitations. First, it did not assess cell-mediated immune response to vaccination. The response to vaccination relies on the development of both humoral and cellular response. Furthermore, cellular immunity, in the absence of positive antibody titers, can prevent severe disease or death from COVID-19 as suggested by some other reports (30-31). The lack of exploration of the cellular immune response precludes us to address the full spectrum of vaccine immunogenicity. Secondly, the short follow-up period (3 months) is not sufficient to draw definitive conclusions. Longer follow-up for clinical outcomes and also the assessment of the cellular response in this special setting are needed.

In summary, even if the immunological response to vaccination is more complex beyond measuring antibody titers, in this large cohort of LT recipients followed-up for 3 months, we showed that antibody response to completed SARS-CoV-2 vaccination is more consistent than that reported in preliminary studies evaluating it after only 4 weeks (75% vs 47%). J o u r n a l P r e -p r o o f 

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

COVID-19 in solid organ transplant recipients: Initial report from the US epicenter

Serologic vaccination response after solid organ transplantation: a systematic review

EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients

Italian association for the study of the liver position statement on SARS-CoV2 vaccination

A 5-YearProspective Multicenter Evaluation of Influenza Infection in Transplant Recipients

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

mRNA Vaccinated Solid Organ Transplant Recipients

Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients

Poor Antibody Response after Two Doses of SARS-CoV-2 vaccine in Transplant Recipients

Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients

Antibody response to SARS-CoV-2 messenger RNA vaccines in liver transplant recipients

Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases

SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients

Comirnaty summary of product characteristics

A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients

Immunosenescence and human vaccine immune responses

Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo

Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression

Mycophenolate mofetil and its mechanisms of action

SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients

A Third Dose of SARS-CoV-2 Vaccine Increases Neutralizing Antibodies Against Variants of Concern in Solid Organ Transplant Recipients

Online ahead of print

Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients